Cipla Ltd
Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157)
- Market Cap ₹ 1,19,870 Cr.
- Current Price ₹ 1,484
- High / Low ₹ 1,702 / 1,310
- Stock P/E 24.3
- Book Value ₹ 397
- Dividend Yield 0.88 %
- ROCE 20.6 %
- ROE 16.4 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 26.0%
Cons
- The company has delivered a poor sales growth of 8.51% over past five years.
- Promoter holding has decreased over last 3 years: -4.43%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty 50 BSE 500 BSE Healthcare BSE 100 BSE 200
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9,457 | 10,132 | 12,118 | 10,768 | 11,390 | 12,374 | 12,659 | 11,303 | 15,381 | 14,345 | 16,574 | 19,045 | |
7,460 | 8,162 | 10,064 | 9,155 | 9,194 | 9,869 | 9,952 | 8,235 | 11,670 | 10,992 | 12,090 | 13,266 | |
Operating Profit | 1,996 | 1,969 | 2,053 | 1,613 | 2,196 | 2,505 | 2,707 | 3,067 | 3,711 | 3,353 | 4,484 | 5,778 |
OPM % | 21% | 19% | 17% | 15% | 19% | 20% | 21% | 27% | 24% | 23% | 27% | 30% |
273 | 140 | 280 | 113 | 257 | 575 | 893 | 654 | 742 | 640 | 1,434 | 1,279 | |
Interest | 128 | 136 | 147 | 39 | 12 | 17 | 36 | 45 | 27 | 22 | 20 | 15 |
Depreciation | 324 | 433 | 443 | 500 | 530 | 570 | 600 | 469 | 547 | 596 | 588 | 574 |
Profit before tax | 1,818 | 1,540 | 1,744 | 1,187 | 1,911 | 2,493 | 2,964 | 3,208 | 3,880 | 3,375 | 5,310 | 6,469 |
Tax % | 24% | 23% | 16% | 18% | 23% | 24% | 22% | 23% | 24% | 26% | 23% | 20% |
1,388 | 1,181 | 1,462 | 975 | 1,469 | 1,888 | 2,318 | 2,468 | 2,958 | 2,513 | 4,077 | 5,158 | |
EPS in Rs | 17.29 | 14.71 | 18.20 | 12.12 | 18.24 | 23.44 | 28.75 | 30.61 | 36.66 | 31.14 | 50.50 | 63.86 |
Dividend Payout % | 12% | 14% | 11% | 16% | 16% | 13% | 14% | 16% | 14% | 27% | 26% | 25% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 9% |
3 Years: | 7% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 16% |
5 Years: | 17% |
3 Years: | 19% |
TTM: | 22% |
Stock Price CAGR | |
---|---|
10 Years: | 8% |
5 Years: | 18% |
3 Years: | 15% |
1 Year: | 0% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 14% |
3 Years: | 14% |
Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 |
Reserves | 9,931 | 10,930 | 11,825 | 12,640 | 13,952 | 15,621 | 17,242 | 19,766 | 22,352 | 24,477 | 27,812 | 31,938 |
877 | 1,381 | 1,132 | 324 | 174 | 0 | 6 | 52 | 23 | 50 | 46 | 117 | |
1,955 | 2,721 | 2,121 | 2,482 | 2,807 | 2,637 | 2,997 | 2,984 | 2,912 | 2,908 | 3,034 | 3,349 | |
Total Liabilities | 12,924 | 15,192 | 15,239 | 15,607 | 17,095 | 18,419 | 20,406 | 22,964 | 25,449 | 27,596 | 31,053 | 35,566 |
3,524 | 3,594 | 3,826 | 4,236 | 4,320 | 4,189 | 4,151 | 4,066 | 3,910 | 3,809 | 3,719 | 3,993 | |
CWIP | 377 | 361 | 551 | 556 | 463 | 297 | 320 | 355 | 268 | 504 | 670 | 523 |
Investments | 3,587 | 4,421 | 4,256 | 4,286 | 4,637 | 5,815 | 7,190 | 9,726 | 10,974 | 11,909 | 13,794 | 17,351 |
5,436 | 6,816 | 6,606 | 6,530 | 7,675 | 8,117 | 8,745 | 8,816 | 10,298 | 11,374 | 12,871 | 13,699 | |
Total Assets | 12,924 | 15,192 | 15,239 | 15,607 | 17,095 | 18,419 | 20,406 | 22,964 | 25,449 | 27,596 | 31,053 | 35,566 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,812 | 1,051 | 1,728 | 2,207 | 1,117 | 1,468 | 2,018 | 3,460 | 2,773 | 3,035 | 3,727 | 3,301 | |
-1,467 | -1,194 | -1,206 | -1,192 | -593 | -1,148 | -1,127 | -3,361 | -2,464 | -2,758 | -2,883 | -2,309 | |
-404 | 180 | -547 | -1,011 | -351 | -473 | -694 | -66 | -427 | -425 | -709 | -1,074 | |
Net Cash Flow | -59 | 37 | -25 | 5 | 173 | -153 | 197 | 33 | -117 | -148 | 135 | -81 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 67 | 74 | 57 | 66 | 75 | 93 | 103 | 98 | 66 | 73 | 59 | 74 |
Inventory Days | 244 | 302 | 217 | 234 | 267 | 232 | 255 | 274 | 215 | 242 | 234 | 241 |
Days Payable | 93 | 126 | 74 | 114 | 139 | 120 | 136 | 133 | 97 | 121 | 121 | 126 |
Cash Conversion Cycle | 217 | 250 | 201 | 185 | 203 | 206 | 222 | 239 | 184 | 195 | 172 | 189 |
Working Capital Days | 126 | 141 | 122 | 116 | 132 | 145 | 146 | 150 | 124 | 177 | 161 | 286 |
ROCE % | 19% | 14% | 14% | 9% | 14% | 16% | 17% | 17% | 18% | 13% | 19% | 21% |
Documents
Announcements
-
Clarification - Intimation Under Regulation 30 Read With Schedule III Of The SEBI (LODR) Regulations, 2015 Submitted On 13Th May, 2025
16h - Clarification on Secretarial Auditor tenure: five years from 89th to 94th AGM.
-
Announcement under Regulation 30 (LODR)-Acquisition
19 May - Cipla subsidiary acquires 26% stake in AMPIN Energy for INR 1.46 Cr to set up captive solar project.
-
Update On USFDA Inspection At Facility Of Sitec Labs Limited In Mahape, Navi Mumbai, India
17 May - USFDA inspection at Sitec Labs classified as Voluntary Action Indicated (VAI) on 16 May 2025.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
16 May - Cipla Q4 FY25 earnings: 9% revenue growth, new US drug approvals, strong India and Africa growth, positive FDA inspections.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 14 May
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Jan 2025TranscriptNotesPPT
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Jan 2024TranscriptNotesPPT
-
Oct 2023Transcript PPT
-
Aug 2023TranscriptPPT
-
Jul 2023Transcript PPT
-
Jul 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptPPT
-
May 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
May 2020TranscriptPPT
-
May 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Nov 2019TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
Jun 2019TranscriptPPT
-
May 2019Transcript PPT
-
May 2019TranscriptNotesPPT
-
Feb 2019TranscriptPPT
-
Feb 2019Transcript PPT
-
Nov 2018TranscriptPPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
May 2016TranscriptNotesPPT
-
Nov 2015TranscriptNotesPPT
-
Aug 2015TranscriptNotesPPT
Market Leadership[1]
# 3rd largest in the India domestic Rx market
# Leadership in Gx
# 1st rank in Respiratory
# Top 5 in Urology and Anti-infectives.
# Over 5 Lac+ no of downloads - Digital Breathe free
# 7,500+ field force detailing to HCPs across the country – 85% of physicians prescribe at least one Cipla product.
# 3rd largest player in private Rx market in SAGA
# Fastest growing generic player in North America.